Depression is a common mental health challenge that affects thinking, behavior, and quality of life, and standard antidepressants do not work for everyone, often causing side effects or delayed responses. Psilocybin, a compound from certain mushrooms, targets serotonin receptors in the brain, lifting mood and promoting neural adaptability. Animal studies with mice, rats, zebrafish, and fruit flies show reduced depression- and anxiety-like behaviors after psilocybin. Clinical trials using synthetic COMP360 in people with treatment-resistant depression report meaningful improvement within days that lasted for weeks. Psychological support before, during, and after the experience is as important as the compound itself, making psilocybin-assisted therapy a whole-person approach.
Depression involves impaired brain neuroplasticity, and brain-derived neurotrophic factor (BDNF) is a key marker of this process. A meta-analysis of 20 studies with 1504 participants found that BDNF levels significantly increase after antidepressant treatment, with a moderate effect size of 0.62. Higher BDNF levels correlated with greater improvement in depression scores. Before treatment, depressed patients had markedly lower BDNF than healthy individuals; after treatment, levels improved but remained slightly lower. Chronic stress and depression are linked to neuronal atrophy in the hippocampus and prefrontal cortex. Emerging treatments like ketamine and non-invasive brain stimulation (transcranial magnetic stimulation) may enhance neuroplasticity and offer faster relief.